Diffuse large B-cell lymphoma
LH Sehn, G Salles - New England Journal of Medicine, 2021 - Mass Medical Soc
Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
Double hit and double expressors in lymphoma: definition and treatment
PA Riedell, SM Smith - Cancer, 2018 - Wiley Online Library
Emerging biologic subsets and new prognostic markers are significantly and adversely
affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas …
affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas …
Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi
F Merli, S Luminari, A Tucci, A Arcari… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at
diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell …
diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell …
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker …
A Rosenwald, S Bens, R Advani, S Barrans… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, MG Da Silva, U Vitolo, A Jack… - Annals of …, 2015 - annalsofoncology.org
Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy
Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using
a time-to-event approach with relapse, re-treatment, and death commonly used as the …
a time-to-event approach with relapse, re-treatment, and death commonly used as the …
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
C Copie-Bergman, P Cuillière-Dartigues… - Blood, The Journal …, 2015 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL) with MYC rearrangement (MYC-R) carries an
unfavorable outcome. We explored the prognostic value of the MYC translocation partner …
unfavorable outcome. We explored the prognostic value of the MYC translocation partner …
End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer–Alliance for Clinical Trials in Oncology …
H Wildiers, M Mauer, A Pallis, A Hurria… - Journal of Clinical …, 2013 - ascopubs.org
Selecting the most appropriate end points for clinical trials is important to assess the value of
new treatment strategies. Well-established end points for clinical research exist in oncology …
new treatment strategies. Well-established end points for clinical research exist in oncology …
[PDF][PDF] Guidelines for the management of diffuse large B-cell lymphoma
1Department of Haematology, Queen Elizabeth Hospital, Birmingham, 2Department of
Clinical Oncology, Christie Hospital, Manchester, 3PET Imaging Centre, King's College …
Clinical Oncology, Christie Hospital, Manchester, 3PET Imaging Centre, King's College …